This review focuses on the underlying rationale for the use of cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (CS + HIPEC) in the treatment of patients with primary gastrointestinal tumors with metastatic peritoneal disease.
Brian W. Loggie, MD
Advertisement
Articles by Brian W. Loggie, MD
Advertisement
Latest Updated Articles
Gastrointestinal Cancers With Peritoneal Carcinomatosis: Surgery and Hyperthermic Intraperitoneal ChemotherapyPublished: July 15th 2015 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Radiotherapy Plus Chemoimmunotherapy Improves Frontline ES-SCLC Prognosis
2
Novel Intratumoral Formulation Shows Responses/Safety in Metastatic Cancers
3
Durvalumab Plus Concurrent CRT Does Not Add Benefit in Stage III NSCLC
4
Matched donor allogeneic CAR T for adult B-ALL: toxicity, efficacy, repeat dosing, and the importance of lymphodepletion
5
